Bafna Pharmaceuticals (NSE:BAFNAPH) Total Equity: ₹961 Mil (As of Mar. 2026)


NSE:BAFNAPH Bafna Pharmaceuticals Ltd NSE:BAFNAPH
60 GF Score
Price ₹194.68
GF Value ₹91.79
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Bafna Pharmaceuticals Total Equity?

Bafna Pharmaceuticals NSE:BAFNAPH +5.00% 60 Total Equity is ₹961 Mil as of Mar. 2026. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 60/100 and a GF Value™ of ₹91.79 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Bafna Pharmaceuticals's total equity for the quarter that ended in Mar. 2026 was ₹961 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Bafna Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Bafna Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bafna Pharmaceuticals Total Equity Chart

Bafna Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 619.64 734.55 808.39 848.07 961.50

Bafna Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 848.07 0.00 912.28 0.00 961.50
NSE:BAFNAPH
60GF Score
Bafna Pharmaceuticals Ltd NSE:BAFNAPH
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bafna Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Bafna Pharmaceuticals's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=1755.324-793.829
=961

Bafna Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=1755.324-793.829
=961

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₹961 Mil mean?
Bafna Pharmaceuticals (NSE:BAFNAPH) has a Total Equity of ₹961 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Bafna Pharmaceuticals and its competitors.
Is Bafna Pharmaceuticals' Total Equity too high?
Bafna Pharmaceuticals' current Total Equity is ₹961 Mil. Overall, Bafna Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' Total Equity compare to ZTS and UTHR?
Bafna Pharmaceuticals' Total Equity of ₹961 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Bafna Pharmaceuticals and its competitors. Bafna Pharmaceuticals's current Total Equity is ₹961 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹91.79, compared to a current price of ₹194.68 — trading 112.1% above its estimated fair value. The current Total Equity is ₹961 Mil. Bafna Pharmaceuticals' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current Total Equity is ₹961 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?

Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued. The current stock price of ₹194.68 is trading 112.1% above its estimated GF Value™ of ₹91.79. GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NSE:BAFNAPH:

  • Total Equity: ₹961 Mil
  • GF Value™: ₹91.79 vs. price of ₹194.68 (112.1% above fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bafna Pharmaceuticals Business Description

Other Exchanges 532989:India
Address Thambu Chetty Street, New No. 68, Old No. 299, Bafna Towers, Chennai, TN, IND, 600001
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
60GF Score

Get the complete analysis for NSE:BAFNAPH

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹194.68
Price
₹91.79
GF Value